Latest Regulatory Clearance News

Lake Resources has raised A$3.8 million through an at-the-market placement priced above recent trading levels, earmarked for environmental and power optimisation work at its Kachi lithium project.

BlinkLab has bolstered its war chest with a A$17.5 million placement, secured a foundational US patent valid through 2041, and made significant progress in its FDA autism diagnostic trial and European ADHD study.

Evolution Mining has agreed to acquire Carnaby Resources via a scheme of arrangement valuing Carnaby at around A$213 million, delivering a 60% premium to shareholders and aiming to de-risk the Greater Duchess project.

ClearView Wealth’s board has approved a fully franked $0.05 special dividend, contingent on the successful completion of Zurich’s $415 million acquisition scheme. The dividend reduces the takeover price but, with franking credits, could enhance total shareholder value.

Harvest Technology Group has inked a non-binding partnership with Ukrainian Technopark to explore integrating its ultra-low-bandwidth Nodestream platform into unmanned defence systems, focusing on resilient communications under electronic warfare conditions.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing in its Phase 1b trial of PYC-003 for Polycystic Kidney Disease, alongside regulatory clearance for an Open-Label Extension allowing continuous dosing up to 24 months.

Control Bionics has closed its Share Purchase Plan, raising $256,500 and pushing total capital raised to $9.75 million, pending shareholder approval for the final tranche.

Solstice Minerals has delivered a standout quarter at its Nanadie Copper-Gold Project, extending mineralisation well beyond the current resource boundary with a massive 629m drill intercept. Backed by a strong $45 million cash position, the company is poised for further resource growth and exploration across its Eastern Goldfields assets.

AFT Pharmaceuticals has received tentative US FDA approval for its Scomara cream to treat Facial Angiofibromas in Tuberous Sclerosis, but US commercialisation is postponed until 2029 due to orphan drug exclusivity. The approval bolsters regulatory prospects in other key markets where AFT anticipates competitive advantages.

PainChek appoints seasoned US medtech executive Karen Holzberger as CEO to spearhead growth following FDA clearance and major US contracts.

EQT’s controlled entity has upped its non-binding offer for Perpetual to A$22.07 per share, a 2% premium on its initial bid. The proposal hinges on Perpetual’s Wealth Management sale and other conditions, with no certainty of a deal.

Orthocell Ltd delivered a standout FY26 with 44% revenue growth to A$13.2 million, powered by accelerating US sales of its nerve repair product Remplir and a robust cash position supporting further expansion.